{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:34:14Z","timestamp":1793385254161,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Johns Hopkins School of Medicine"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ygyno.2017.02.019","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T01:32:46Z","timestamp":1487035966000},"page":"208-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":184,"title":["Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation"],"prefix":"10.1016","volume":"145","author":[{"given":"Stephanie","family":"Ricci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N.","family":"Fader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.02.019_bb0005","series-title":"Blaustein's Pathology of the Female Genital Tract","first-page":"487","article-title":"Mesenchymal tumors of the uterus","author":"Zaloudek","year":"1994"},{"issue":"3","key":"10.1016\/j.ygyno.2017.02.019_bb0010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/IGC.0000000000000372","article-title":"Trends in the treatment of uterine leiomyosarcoma in the medicare population","volume":"25","author":"Foley","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0015","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/cncr.26333","article-title":"A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma","volume":"118","author":"Zivanovic","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2017.02.019_bb0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2559.2009.03231.x","article-title":"Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients","volume":"54","author":"Abeler","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0025","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ijc.22239","article-title":"Incidence patters of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978\u20132001: an analysis of 26,758 cases","volume":"119","author":"Toro","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0030","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/bjc.2013.2","article-title":"The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium","volume":"108","author":"Felix","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0035","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1525-1438.2007.01025.x","article-title":"The risk of developing uterine sarcoma after tamoxifen use","volume":"18","author":"Lavie","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0040","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00129039-200412000-00008","article-title":"Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study","volume":"12","author":"Kelley","year":"2004","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"4 Suppl","key":"10.1016\/j.ygyno.2017.02.019_bb0045","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D'Angelo","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0055","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/PAS.0b013e31820ca624","article-title":"Histopathologic prognostic factors in stage I leiomyosarcoma of the uterus: a detailed analysis of 27 cases","volume":"35","author":"Wang","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0060","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ygyno.2009.02.020","article-title":"Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis","volume":"113","author":"Guntupalli","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0065","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1007\/s00330-013-2819-9","article-title":"How to differentiate benign from malignant myometrial tumours using MR imaging","volume":"23","author":"Thomassin-Naggara","year":"2013","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0070","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-11-3058","article-title":"A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma","volume":"18","author":"Shan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0075","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/onc.2009.381","article-title":"Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling","volume":"29","author":"Beck","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0080","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neo.2014.12.007","article-title":"Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome","volume":"17","author":"Barlin","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ygyno.2008.02.026","article-title":"The utility of preoperative endometrial sampling for the detection of uterine sarcomas","volume":"110","author":"Bansal","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0090","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1007\/s00330-013-2819-9","article-title":"How to differentiate benign from malignant myometrial tumours using MR imaging","volume":"23","author":"Thomassin-Naggara","year":"2013","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0095","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jmri.24998","article-title":"Comparison of the diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted MRI in the differentiation between uterine leiomyosarcoma\/smooth muscle tumor with uncertain malignant potential and benign leiomyoma","volume":"43","author":"Lin","year":"2016","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0100","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jmig.2016.01.022","article-title":"The role of endometrial biopsy in the preoperative detection of uterine leiomyosarcoma","volume":"23","author":"Hinchcliff","year":"2016","journal-title":"J. Minim. Invasive Gynecol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0105","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1525-1438.2002.01086.x","article-title":"Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus","volume":"12","author":"Goto","year":"2002","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0110","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1006\/gyno.2000.6081","article-title":"Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging","volume":"80","author":"Umesaki","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0115","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.23245","article-title":"Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy","volume":"112","author":"Kapp","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2017.02.019_bb0120","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.6004\/jnccn.2015.0162","article-title":"Uterine sarcoma, version 1.2016: featured updates to the NCCN guidelines. National Comprehensive Cancer Network","volume":"13","author":"Koh","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0125","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0959-8049(97)00040-3","article-title":"Uterine sarcomas in Norway 1956\u20131992: incidence, survival and mortality","volume":"33","author":"Nordal","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0130","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0090-8258(84)90041-6","article-title":"Uterine sarcomas: a clinicopathogic study, 1965\u20131981","volume":"18","author":"Marchese","year":"1984","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0135","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ygyno.2003.10.044","article-title":"The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990\u20131999) at the Massachusetts General Hospital","volume":"92","author":"Dinh","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0090-8258(03)00478-5","article-title":"Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus","volume":"91","author":"Leitao","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0145","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0150","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/gyno.2002.6840","article-title":"Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma","volume":"87","author":"Leitao","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0155","first-page":"2004","article-title":"Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival","volume":"81","author":"Burt","year":"2006","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmig.2010.10.001","volume":"18","year":"2011","journal-title":"J. Minim. Invasive Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.02.019_bb0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jmig.2014.08.781","article-title":"Outcomes of occult uterine leiomyosarcoma after surgery for presumed uterine fibroids: a systematic review","volume":"22","author":"Pritts","year":"2015","journal-title":"J. Minim. Invasive Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.02.019_bb0170","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/AOG.0000000000001242","article-title":"Risk of occult uterine sarcoma in women undergoing hysterectomy for benign indications","volume":"127","author":"Kho","year":"2016","journal-title":"Obstet. Gynecol."},{"issue":"12","key":"10.1016\/j.ygyno.2017.02.019_bb0180","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.2014.9005","article-title":"Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation","volume":"312","author":"Wright","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ygyno.2017.02.019_bb0185","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/AOG.0000000000000642","article-title":"Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications","volume":"125","author":"Mahnert","year":"2015","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.02.019_bb0190","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jmig.2014.10.022","article-title":"Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women","volume":"22","author":"Lieng","year":"2015","journal-title":"J. Minim. Invasive Gynecol."},{"issue":"368","key":"10.1016\/j.ygyno.2017.02.019_bb0205","article-title":"Clinical application of diffusion-weighted imaging for preoperative differentiation between uterine leiomyoma and leiomyosarcoma","volume":"210","author":"Sato","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0215","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ygyno.2011.04.021","article-title":"The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma","volume":"122","author":"Park","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0220","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1002\/cncr.28844","article-title":"Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma","volume":"120","author":"George","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2017.02.019_bb0225","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/AOG.0000000000001187","article-title":"Occult uterine sarcoma and leiomyosarcoma: incidence of and survival associated with morcellation","volume":"127","author":"Raine-Bennett","year":"2016","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0230","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1525-1438.2007.01126.x","article-title":"Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease","volume":"18","author":"Einstein","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0235","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ygyno.2013.11.024","article-title":"The value of re-exploration in patients with inadvertently morcellated uterine sarcoma","volume":"132","author":"Oduyebo","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.02.019_bb0240","first-page":"414","article-title":"Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma","volume":"83","author":"Parker","year":"1994","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.02.019_bb0245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2015.01.025","article-title":"Preoperative patient stratification results in low rates of occult uterine malignancy in women undergoing uterine surgery and morcellation","volume":"137","author":"Ricci","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.02.019_bb0250","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ajog.2015.08.047","article-title":"Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation","volume":"214","author":"Harris","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.02.019_bb0255","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/AOG.0000000000000421","article-title":"Contained power morcellation within an inufflated isolation bag","volume":"124","author":"Cohen","year":"2014","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.02.019_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.08.076","article-title":"Contained tissue extraction using power morcelaltion: prospective evaluation of leakage parameters","volume":"214","author":"Cohen","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0265","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ygyno.2013.08.037","article-title":"Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?","volume":"131","author":"Ricci","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0270","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/MNM.0b013e32834e41a6","article-title":"Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging","volume":"33","author":"Sharma","year":"2012","journal-title":"Nucl. Med. Commun."},{"issue":"9","key":"10.1016\/j.ygyno.2017.02.019_bb0275","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.1985.3.9.1240","article-title":"A randomized clinical trial of adriaymcyin in uterine sarcomas: a Gyencologic Oncology Group study","volume":"3","author":"Omura","year":"1985","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0280","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.27942","article-title":"Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase II trial (SARC 005)","volume":"119","author":"Hensley","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0295","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ejca.2008.01.019","article-title":"Phase III randomized study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: a European Organization for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874)","volume":"44","author":"Reed","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0300","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mds545","article-title":"A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group","volume":"24","author":"Pautier","year":"2013","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.02.019_bb0305","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ygyno.2012.02.014","article-title":"Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis","volume":"125","author":"Leitao","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0310","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a gynecologic oncology group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0315","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a gynecologic oncology group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0320","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","article-title":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial","volume":"20","author":"Hensley","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.02.019_bb0325","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1996.0220","article-title":"Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study","volume":"62","author":"Sutton","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0330","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ygyno.2009.09.011","article-title":"Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"115","author":"Hensley","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0335","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0340","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0345","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2016.03.024","article-title":"Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072","volume":"142","author":"Benson","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2017.02.019_bb0350","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2014.58.3781","article-title":"Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology\/Gynecologic Oncology Group study","volume":"33","author":"Hensley","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2017.02.019_bb0355","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1634\/theoncologist.2015-0245","article-title":"A phase Ib\/II study of gemcitabine and docetaxel in combination with pazopanib for the neoadjuvant treatment of soft tissue sarcomas","volume":"20","author":"Munhoz","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0360","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): a unique mechanism of action","volume":"9","author":"D'Incalci","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0365","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ijc.29023","article-title":"Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1","volume":"136","author":"Dossi","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0370","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2011.09.019","article-title":"A phase II evaluation of trabectedin in the treatment of advanced, persistent or recurrent uterine leiomyosarcoma: a gynecologic oncology group study","volume":"124","author":"Monk","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0375","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.10505","article-title":"LMS-02: a phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): first results in patients with u-LMS","volume":"31","author":"Pautier","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.019_bb0380","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.10503","article-title":"A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS)","volume":"33","author":"Demetri","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"10043","key":"10.1016\/j.ygyno.2017.02.019_bb0385","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2017.02.019_bb0400","doi-asserted-by":"crossref","first-page":"243298","DOI":"10.1155\/2015\/243298","article-title":"Potential therapeutic targets in uterine sarcomas","volume":"2015","author":"Cuppens","year":"2015","journal-title":"Sarcoma"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2017.02.019_bb0410","article-title":"PD-1 and PD-L1 expression in 1599 gynecological malignancies - implications for immunotherapy","volume":"137","author":"Herzog","year":"2015","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817301312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817301312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T09:06:46Z","timestamp":1719047206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817301312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0090825817301312"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}